Shortened Duration of Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: A Contemporary Clinical Review
Kevin S Tang, Shoujit Banerjee, George Tang, Pranav M Patel, Antonio H Frangieh · 2023
Read Shortened Duration of Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: A Contemporary Clinical Review by Kevin S Tang, Shoujit Banerjee, George Tang, Pranav M Patel, Antonio H Frangieh (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10782423.txt.
Description
Kevin Tang and four co-authors review how long patients should take two blood-thinning drugs after a heart stent is placed. Their 2023 review notes that stents have improved fast, yet the right length of dual therapy stayed debated. The pair of drugs guards against clots in the stent, but it also raises the risk of bleeding.
Older guidance favored twelve months of dual therapy, and longer for some patients. Newer trials and safer drug-coated stents have shifted the field toward shorter courses. Cutting months of therapy lowers major bleeding while modern stents keep clot risk in check. The authors walk through current guidelines, the fresh proof behind them, and the gaps that remain. Heart teams can use the review to tailor duration to each patient's clot and bleed risks.
Catalog record
| CREATOR | Kevin S Tang, Shoujit Banerjee, George Tang, Pranav M Patel, Antonio H Frangieh |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |